Hemofarm a.d.

Hemofarm a.d. (full legal name: Hemofarm a.d. Farmaceutsko-hemijska industrija Vršac), a member of STADA Group, is a Serbian pharmaceutical company based in Vršac, Serbia. Founded in 1960, it is one of the largest domestic producer and exporter of medicines in Serbia. Hemofarm currently operates in more than 30 countries on 3 continents and has around 3,000 employees.

Hemofarm a.d.
Native name
Хемофарм а.д.
Joint-stock company
IndustryPharmaceuticals
Founded28 August 1998 (1998-08-28) (current form)
1960 (1960) (founded)
Headquarters
Beogradski put bb, Vršac
,
Serbia
Key people
Ronald Seeliger (CEO)
ProductsPharmaceuticals, Prescription drugs
Revenue €337.37 million (2018)[1]
€26.47 million (2018)[1]
Total assets €436.09 million (2018)[2]
Total equity €296.34 million (2018)[2]
OwnerSTADA (100%)
Number of employees
3,134 (2018)
Websitewww.hemofarm.com

The core activity represents the manufacture of Rx and OTC medicines and products. Portfolio includes over 140 INNs, with about 280 forms and dosage forms.

History

Hemofarm was established on 1 June 1960 in Vršac. In 2003, it opened the first factory for the production of medicine in entity Republika Srpska, Bosnia and Herzegovina. As of 2003, Hemofarm consisted of 21 subsidiaries, 12 of which were located in Serbia and rest in Montenegro.[3]

In 2004, the company acquired four other Serbian concerns, increasing its market share from 15% to 45% in the process.[4] As of 2011, the company has a market share in terms of production and import of 30.7%.[5]

Hemofarm was bought by the German STADA Arzneimittel pharmaceutical group for 480 million euros in 2006.[6] Since 9 August 2009 Hemofarm has been a member of the German STADA Group.

In August 2016, Hemofarm bought the assets of a Serbian minor pharmaceutical company "Ivančić i sinovi" for undisclosed amount.[7]

Research and development

Hemofarm’s R&D division was established in 1990, and it has been recognized by STADA as a competence center for development of new generic products not only for local and regional markets, but also for the whole STADA Group. An intensive development of products intended for registration and sale in the demanding European Union market started in 2007.

References
  1. "КОНСОЛИДОВАНИ БИЛАНС УСПЕХА (2018) - Хемофарм". apr.gov.rs (in Serbian). Retrieved 28 September 2019.
  2. "КОНСОЛИДОВАНИ БИЛАНС СТАЊА (2018) - Хемофарм". apr.gov.rs. Retrieved 28 September 2019.
  3. "Bosnian Serb, Serbian premiers inaugurate pharmaceutical plant". Asia Africa Intelligence Wire. February 21, 2003. Retrieved 2008-10-02.
  4. Doing Business with Serbia By Marat Terterov, Consultant Editor, Marat Terterov, Inc NetLibrary; Published by GMB Publishing Ltd, 2006; ISBN 1-905050-68-2, ISBN 978-1-905050-68-0.
  5. Lazarević, Igor. "Konsolidacija farmaceutskog tržišta Srbije". scribd.com (in Serbian). Retrieved 28 July 2014.
  6. "Stada Says Strength of Russian Unit May Attract Bids". Blommberg. 11 January 2013. Retrieved 9 April 2013.
  7. Popadić, Jelena (25 September 2016). "Ko je kupio „Ivančić i sinove"". politika.rs (in Serbian). Retrieved 13 March 2018.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.